InstaMed appoints Tracy Gibbs, PhD, as CEO ahead of August 3 product launch

The 14-month-old biotechnology company said it plans to introduce five oral dissolving peptide films as it expands its needle-free delivery platform, backed by a double-blinded pharmacokinetic study and nine pending patents.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.